CSBRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:57):

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States...

Stats
本日の出来高	1 969.00
平均出来高	3 990.00
時価総額	64.43M
EPS	$-0.160 ( 2024-03-20 )
次の収益日	( $-0.160 ) 2024-07-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.58
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-09	Davis Brady	Buy	68 000	Option to purchase Common Stock
2023-10-09	Davis Brady	Buy	7 500	Option to purchase Common Stock
2023-10-09	Davis Brady	Buy	135 000	Option to purchase Common Stock
2024-01-12	Mendelson Daniel Newman	Buy	1 000	Common Stock
2024-01-11	Mendelson Daniel Newman	Buy	2 000	Common Stock

INSIDER POWER
88.92
Last 100 transactions
Buy: 1 237 465 \| Sell: 480 213

Champions Oncology Inc 相関

10 最も正の相関
VCSA	0.965
OPTN	0.965
AGZD	0.957
STSA	0.955
TOI	0.945
IMRX	0.94
ONCS	0.94
ADSE	0.933
TCDA	0.931
VSTA	0.93

10 最も負の相関
ARNA	-0.953
CCRC	-0.938
PBFS	-0.922
MACK	-0.917
APEN	-0.912
IBEX	-0.91
CLRO	-0.907
IMMR	-0.905
STIM	-0.899
SEDG	-0.896

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Champions Oncology Inc 財務諸表

Annual	2023
収益:	$53.87M
総利益:	$24.34M (45.18 %)
EPS:	$-0.390

FY	2023
収益:	$53.87M
総利益:	$24.34M (45.18 %)
EPS:	$-0.390

FY	2022
収益:	$49.11M
総利益:	$25.48M (51.88 %)
EPS:	$0.0415

FY	2021
収益:	$41.04M
総利益:	$19.59M (47.74 %)
EPS:	$0.0300

Financial Reports:

No articles found.

Champions Oncology Inc

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.